Daily use of consensus interferon: One-year treatment results for chronic hepatitis C patients relapsing or non-responding to previous interferon
Küçük Resim Yok
Tarih
2000
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Background/aim: The optimal dose, duration and frequency of interferon treatment for chronic hepatitis C is not clear. Preliminary hepatitis C virus kinetic studies have suggested that daily interferon is more advantageous than thrice in a week administration. Recently, a synthetic recombinant interferon, consensus interferon, has been approved for clinical application. There is no data available about daily use of consensus interferon. Methods: Our study protocol was designed to investigate the efficacy of long-term (12 month) daily consensus interferon therapy for chronic hepatitis C patients, who have either relapsed or not responded to previous interferon therapy. Eleven patients were included in the study. Results: Overall, eight (72%) patients became serum HCV-RNA negative. Of these, 60% (3/5) were among previous non-responders and 83% (5/6) were among previous relapsers. Conclusions: Our preliminary data suggests that daily use of consensus interferon provides encouraging results in relapsers and non-responders. However, further time is needed to evaluate the sustained response rate.
Açıklama
Anahtar Kelimeler
Consensus interferon, Hepatitis C
Kaynak
Turkish Journal of Gastroenterology
WoS Q Değeri
Scopus Q Değeri
Q3
Cilt
11
Sayı
3
